Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on pioneering, developing, and commercializing DNA medicines. Its overarching goal is to treat ailments and provide protection against diseases stemming from human papillomavirus (HPV), various cancers, and infectious pathogens. The company's proprietary DNA medicines platform incorporates precisely engineered SynCon technology, which identifies and optimizes the DNA sequence of target antigens, alongside CELLECTRA smart devices designed for efficient delivery of these DNA plasmids. Inovio is currently conducting and planning clinical investigations into its DNA therapies for a broad spectrum of indications. These include HPV-associated precancerous lesions, such as cervical, vulvar, and anal dysplasia; HPV-related malignancies, including those of the head and neck, cervix, anus, penis, vulva, and vagina; and other HPV-driven conditions like recurrent respiratory papillomatosis. Furthermore, its development pipeline addresses glioblastoma multiforme, prostate cancer, HIV, Ebola, Middle East Respiratory Syndrome (MERS), and Lassa fever. Inovio collaborates extensively with a diverse group of partners and institutions, including ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. Specific collaborations include an agreement with Richter-Helm BioLogics GmbH & Co. KG to support the investigational COVID-19 DNA vaccine, INO-4800, and a partnership involving the International Vaccine Institute and Seoul National University Hospital. Founded in 1979, the company maintains its corporate headquarters in Plymouth Meeting, Pennsylvania.